ClinicalTrials.gg
RecruitingNCT07263035US-DASHUpdated Apr 9, 2026

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

A Phase 4 interventional study of Furosemide intravenous solution and Furosemide intravenous solution in Heart Failure, Heart Failure - NYHA II - IV and Heart Failure Acute, sponsored by Lakeland Regional Health Systems, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Lakeland Regional Health Systems, Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing furosemide in Heart Failure — 5 open to participants now, 5 under way, 1 of them phase 3. Furosemide · Heart Failure.

Planned enrollment
3rd of 35
600 · median 42
Started
2026
the only one that year
Phase 4
17 of 36
4 open now
Registered
36th of 36
by date

Among the 36 studies testing furosemide in Heart Failure, this one is the 3rd largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2026, is one of 17 in phase 4, and was the 36th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 36 studies testing furosemide in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About furosemide

Furosemide: first FDA approval 1966 (LASIX), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing furosemide in Heart Failure, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if increasing the dose of diuretics to achieve a higher urine sodium target produces better clinical results when treating patients hospitalized with acute heart failure when compared to lower urine sodium target and standard of care.

The main questions it aims to answer are:

  1. Does targeting a higher urine sodium goal achieve greater natriuresis and diuresis?
  2. Does targeting a higher urine sodium goal reduce frequency of hospital readmissions?
  3. Does targeting a higher urine sodium goal reduce hospital length of stay?

Researchers will compare natriuresis-guided arms with standard of care to see if targeting higher natriuresis goals improves significantly over current practice.

Participants will submit urine samples at routine intervals after being given diuretics to evaluate urine sodium concentration. If urine sodium is low then diuretic dose will be increased.

Read the detailed description

Patients will be randomized into one of three groups: 50 micromolar natriuresis, 85 micromolar natriuresis, and standard of care. The natriuresis arms will have urine sodium assessed two to four hours administration of intravenous diuretics. If the natriuretic response is inadequate they will immediately receive a higher dose of diuretic. This process will be repeated for the first 72 hours of admission.

03

Conditions studied

  • Heart Failure
  • Heart Failure - NYHA II - IV
  • Heart Failure Acute
  • Acute Heart Failure (AHF)

Browse trials for

Keywords

  • Urine sodium
  • Diuretics
  • Lasix
  • heart failure
  • Acute CHF
  • acute HFrEF
  • Acute HFpEF
  • Natriuresis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • The study will target adults 18 years of age or older admitted to Lakeland Regional Medical Center who:

    • Have a primary diagnosis of acute decompensated heart failure, and
    • Have at least one of the following signs of hypervolemia:

      • Bilateral lower extremity pitting edema
      • Jugular venous distension
      • Hepatojugular reflex
      • Crackles on pulmonary exam, or
      • Chest x-ray demonstrating pulmonary edema or pleural effusions

Exclusion Criteria:

  • Exclusion criteria include:

    • Admission to the intensive care unit
    • Presence of ST-elevated myocardial infarction
    • Presence of type 1 non-ST elevated myocardial infarction
    • Dyspnea primarily due to non-cardiac cause as judged by the emergency medicine physician or admitting physician
    • Use of supplemental oxygen totaling at least 3 L per minute or greater at baseline
    • Anuria
    • End-stage renal disease per KDIGO criteria
    • Dialysis use
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    Control

    Traditional diuretic dosing adjustment per provider

    Drug: Furosemide intravenous solution

  • Experimental
    50 mmol/L urine sodium

    Diuretics will be titrated to achieve a urine sodium concentration of 50 mmol/L

    Drug: Furosemide intravenous solution

  • Experimental
    85 mmol/L urine sodium

    Diuretics will be titrated to achieve a urine sodium concentration of 85 mmol/L

    Drug: Furosemide intravenous solution

Interventions

06

What researchers measure

Primary outcomes

  1. Natriuresis at 24 hours

    24-hour natriuresis as measured by urine sodium in a 24-hour urine collection

    Time frame: 24 hours

Secondary outcomes

  1. Natriuresis at 48 hours

    Total urine sodium assessed by 24-hour urine collection

    Time frame: 48 hours after enrollment in trial

  2. Diuresis at 24 hours

    Total urine volume assessed by 24 hour collection

    Time frame: 24 hours after enrollment

  3. Diuresis at 48 hours

    Total urine volume assessed via 24-hour collection

    Time frame: 48 hours after enrollment

  4. Length of Stay

    Duration of hospitalization

    Time frame: From the date and time of admission order until the date and time of discharge order, assessed for each participant up to 30 days after admission or death from any cause, whichever comes first.

  5. Readmission of any cause at 30 days

    Proportion of participants who experience an unplanned hospital readmission for any cause within 30 days after the index hospital discharge.

    Time frame: 30 days after discharge

  6. Readmission rate of any cause at 90 days

    Proportion of participants who experience an unplanned hospital readmission for any cause within 90 days after the index hospital discharge.

    Time frame: 90 days after the time of discharge

  7. Readmission rate of Heart failure

    Proportion of participants who experience an unplanned hospital readmission specifically for heart failure within 30 days after the index hospital discharge.

    Time frame: 30 days

  8. Readmission rate for heart failure

    Proportion of participants who experience an unplanned hospital readmission specifically for heart failure within 90 days after the index hospital discharge.

    Time frame: 90 days

  9. Weight change

    Difference in weight from admission compared to discharge

    Time frame: Weight assessed at baseline within 24 hours of hospital admission and at discharge, with the discharge weight measured on the discharge day up to 30 days after admission.

  10. Net fluid balance

    Cumulative difference between total fluid intake and output during the hospitalization

    Time frame: Net fluid balance assessed from baseline Day 1 of admission through hospital discharge, with discharge assessment on the discharge day up to 30 days after admission.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 14 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 4, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07263035
Lead sponsor
Lakeland Regional Health Systems, Inc.
Responsible party
Anas Bizanti, MD (Associate Program Director, Internal Medicine Residency - Principal Investigator, Lakeland Regional Health Systems, Inc.) — Principal investigator
First posted
Dec 4, 2025
Start date
Apr 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Andrew Lurie, DO
Contact
Andrew.Lurie@myLRH.org
8636871100 ext. 1443
Anas Bizanti, MD
Contact
anas.bizanti@mylrh.org
8636871100 ext. 1443
Andrew Lurie, DO
study director · Lakeland Regional Hospital
Anas Bizanti, MD
principal investigator · Lakeland Regional Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion